Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
NKTR
Stock Latest News
Ratings
Promising Data from REZOLVE-AA Trial Positions REZPEG as a Safer, Effective Treatment for Alopecia Areata with Undervalued Stock
8d ago
NKTR
Premium
Ratings
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment
9d ago
NKTR
Premium
Ratings
Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
9d ago
NKTR
Premium
Ratings
Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target
9d ago
NKTR
Premium
The Fly
Nektar price target raised to $135 from $120 at H.C. Wainwright
9d ago
NKTR
Premium
The Fly
Nektar price target raised to $115 from $98 at Oppenheimer
9d ago
NKTR
Premium
Company Announcements
Nektar Therapeutics Announces Phase 2b Trial Results
9d ago
8K
NKTR
Premium
The Fly
Nektar’s rezpegaldesleukin shows proof of concept in Phase 2b alopecia trial
9d ago
NKTR
Premium
The Fly
Nektar to hold conference call on Phase 2b Rezpegaldesleukin results
10d ago
NKTR
Premium
Weekend Updates
Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts
27d ago
OVV
CODX
Premium
The Fly
Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls
29d ago
KD
PD
Premium
The Fly
Nektar price target raised to $121 from $99 at Jefferies
29d ago
NKTR
Premium
The Fly
Citi starts Nektar with Buy, opens ‘positive catalyst watch’
29d ago
NKTR
Premium
Company Announcements
Nektar Therapeutics Announces Chief Legal Officer Departure
1M ago
8K
NKTR
Premium
Ratings
Hold Rating Maintained Amid Uncertainty in Rezpeg Trial Outcomes and Ongoing Research
1M ago
NKTR
Premium
Ratings
Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment
1M ago
NKTR
Premium
The Fly
Nektar files automatic mixed securities shelf
1M ago
NKTR
Premium
Company Announcements
Nektar Therapeutics Reveals Promising Phase 2b Trial Results
2M ago
8K
NKTR
Premium
The Fly
Nektar presents new data from REZOLVE-AD study of ACAAI
2M ago
NKTR
Premium
Company Announcements
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation
2M ago
NKTR
Premium
Company Announcements
Nektar Therapeutics Reports Q3 2025 Financial Results
2M ago
NKTR
Premium
Ratings
Hold Rating on Nektar Therapeutics Amid Uncertainties in Rezpeg’s Clinical Trials and Market Potential
2M ago
NKTR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
